Product image of Mirabegron Stada (Mirabegron) supplied by GNH India

Mirabegron Stada

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegron Stada (Mirabegron)

Mirabegron, the active ingredient in Mirabegron Stada, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency, and urge incontinence in adults.

GNH India supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe distribution across EU and global markets. Customers benefit from reliable supply chains and responsive technical support.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirabegron is used to manage symptoms of overactive bladder, a condition characterized by involuntary detrusor contractions.

  • Overactive bladder: reduces urgency episodes and increases functional bladder capacity.
  • Urinary urgency: alleviates sudden, compelling urge to void.
  • Urinary frequency: decreases daytime voiding frequency, improving quality of life.

How It Works

  • Mirabegron activates β3‑adrenergic receptors located in the detrusor smooth muscle of the bladder. Stimulation of these receptors leads to relaxation of the bladder wall, which increases bladder storage capacity and reduces involuntary contractions that cause urgency and frequency.

Side Effects

Common Side Effects

  • Hypertension: elevated blood pressure may be observed.
  • Headache: mild to moderate intensity.
  • Nasopharyngitis: upper respiratory tract infection symptoms.
  • Constipation: reduced bowel movements.
  • Dry mouth: decreased salivation.
  • Urinary retention: difficulty initiating urination.

Serious or Rare Side Effects

  • Severe hypertension: markedly high blood pressure requiring medical attention.
  • Tachycardia: rapid heart rate.
  • Angioedema: swelling of face, lips, or throat.
  • Acute urinary retention leading to obstruction.
  • Allergic reactions: rash, pruritus, or anaphylaxis.
  • Myocardial infarction: rare cardiac events.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

  • Blood pressure assessment: measure baseline and monitor regularly.
  • Urinary retention monitoring: watch for signs of incomplete bladder emptying.
  • Concomitant antihypertensive review: adjust doses if needed.
  • Hepatic impairment: use with caution in severe liver disease.
  • Uncontrolled hypertension: avoid use in patients with markedly elevated BP.
  • Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Mirabegron may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase mirabegron exposure.
  • Strong CYP2D6 inducers (e.g., rifampin): reduce mirabegron effectiveness.
  • Anticholinergic agents: may exacerbate urinary retention.

Moderate Interactions (Monitor Closely):\n- Antihypertensives: possible reduction in blood‑pressure‑lowering effect.

  • Diuretics: may increase risk of hypertension.
  • NSAIDs: additive effect on blood pressure.
  • Beta‑blockers: potential for altered cardiovascular response.
  • Digoxin: monitor serum levels due to possible interaction.

Frequently Asked Questions

Mirabegron Stada is prescribed to treat overactive bladder symptoms, including urinary urgency, increased daytime frequency, and urge incontinence. It helps relax the bladder muscle, allowing it to store more urine and reducing the frequency of involuntary contractions.

Mirabegron works by selectively activating β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation relaxes the smooth muscle, increasing bladder capacity and decreasing involuntary contractions that cause urgency and frequency.

The dosage of Mirabegron Stada is determined by the prescribing healthcare professional based on the patient’s condition, response, and tolerability. The prescriber will select the appropriate strength and dosing schedule for each individual.

Safety data for mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Mirabegron Stada, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class for overactive bladder is antimuscarinic agents such as oxybutynin. Mirabegron differs by targeting β3‑adrenergic receptors rather than muscarinic receptors, often resulting in a lower incidence of dry mouth and constipation, though it may be associated with higher blood‑pressure effects.

Mirabegron Stada should be stored at or below 25 °C in its original packaging, protected from moisture and direct sunlight. Do not store in a refrigerator or freezer unless otherwise specified by the manufacturer.

Mirabegron Stada is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not chewed or crushed.

Serious risks include significant hypertension, tachycardia, acute urinary retention, angioedema, and rare cardiac events such as myocardial infarction. Patients should seek immediate medical attention if they experience severe headache, chest pain, rapid heartbeat, or swelling of the face or throat.

Mirabegron Stada is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron or any excipients. Caution is also advised for individuals with a history of urinary retention or narrow-angle glaucoma.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT